Form 4: Vaxcyte CEO Sells Shares Under 10b5-1 Plan

Vaxcyte, Inc. CEO Grant Pickering has sold a significant number of common shares under a pre-arranged trading plan.

Summary

• Vaxcyte, Inc. CEO Grant Pickering reported the sale of common stock on June 26, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted on March 3, 2026.
• A total of 6,683 shares were sold at a weighted-average price of $54.275.
• An additional 9,137 shares were sold at a weighted-average price of $55.265.
• Another 6,417 shares were sold at a weighted-average price of $56.121.
• Smaller tranches of shares were also sold, with prices ranging from $53.755 to $56.60.
• Following these transactions, Pickering directly owns 452,466 shares and indirectly owns 134,903 shares through trusts for his children.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by the CEO, despite being conducted under a pre-arranged plan.

Negatives

• The CEO sold a substantial amount of company stock, which could be perceived negatively by the market.

Risks

• The sale of shares by a CEO, even under a 10b5-1 plan, can sometimes be interpreted as a lack of confidence in the company's future prospects by investors.
• The weighted-average prices indicate a range of sales, suggesting potential market fluctuations around the transaction dates.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider sales, particularly by CEOs, are common events that investors closely monitor. While a Rule 10b5-1 plan provides an affirmative defense against insider trading allegations, the sheer volume and timing of such sales can still influence market perception and investor sentiment towards Vaxcyte, Inc. (PCVX).

Stakeholder Impact

• Shareholders: May interpret the CEO's stock sales as a potential signal of reduced confidence, potentially impacting share price. However, the 10b5-1 plan mitigates concerns about illegal insider trading.
• Employees: May feel a degree of uncertainty if the CEO's sales are perceived as a negative indicator for the company's future performance.
• Management: The CEO's actions are subject to scrutiny, and while this sale is compliant, it sets a precedent for future transactions.

Key Dates

Recommendation

The filing reports a sale of stock by the CEO under a Rule 10b5-1 plan. While this is a standard compliance mechanism, significant insider selling can be a cautionary signal. Without further context on the company's performance or the reasons behind the sale (beyond the plan itself), a 'hold' recommendation is prudent, allowing investors to monitor future developments.

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, CEO, Grant Pickering, Beneficial Ownership